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ABSTRACT
Various types of stressful conditions can have unique and important effects on immunity
and can lead to dramatic consequences to health. For my University Scholar project, the
characteristic biomarker signatures produced from a set of diverse stressors (e.g. psychological,
biological and chemical) are being investigated. A biomarker signature is a distinctive biological
indicator of a specific condition. High-throughput tools for the measurement of different cellular
products have the potential to further our understanding of human disease and facilitated the
identification of new biomarkers in all areas of medicine. The hypothesis that each form of
stress, psychological, chemical and physical, will elicit different biomarker signatures is being
tested. In order to examine the biomarker signatures associated with various stressors, samples
from individuals who have experiences one of several forms of stress will be evaluated. The
biological samples to be tested include human saliva samples taken from patients who had
experienced psychological trauma. We hypothesize that distinctive changes to the biomarker
signature found in these patients’ saliva may facilitate the identification of those with post
traumatic stress disorder (PTSD) and ultimately may enable a more effective treatment regimen.
To quantify the differential expression profiles of the salivary components of the biomarker
signature (including interleukins, chemokines, TNF, interferon, heat shock proteins, melatonin,
and procalcitonin) traditional enzyme-linked immunosorbent assay (ELISA) as well as Surface
Plasmon Enhanced Fluorescence (SPEF) techniques will be utilized. By categorizing the unique
endogenous responses that are associated with each stressful condition, better diagnosis could be
made and the effects of different stresses may be better predicted and controlled. Categorizing
and quantifying different biomarker signatures of individuals experiencing different stressors
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will help provide insight into some of the health consequences which may result from these
stressors.

INTRODUCTION
Biomarker Signatures
Biomarkers are features that can be objectively measured and evaluated as an indicator of
a normal biological process, a pathogenic process, or a pharmacological response to a therapeutic
intervention (Biomarkers Definitions Working Group. 2001). A biomarker can be used as an
indicator of a biological state; it is a characteristic that is objectively measured and evaluated as
an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to
a therapeutic intervention. Limits to using biomarkers as a diagnostic tool exist. Using only a
single indicator leaves room for false positives in the population of healthy individuals with high
levels of that specific substance, or false negatives, diseased individuals with lower levels of the
indicator. This inaccuracy can be reduced by use of biomarker signatures. A biomarker signature
is an integration of simultaneous biomarker measurements that generate a predictive pattern or
signature of a biological state. Analysis of large analyte sets can generate biomarker signatures
of disease or stress exposure that has diagnostic potential.
In addition to diagnostic uses, biomarker signatures have potential implications with
therapeutics. Certain therapeutic interventions can only be effective in subpopulations
(Trusheim, Berndt, Douglas 2007). Biomarker signatures have the potential to be useful for
identifying patients that are more likely to benefit or to experience an adverse reaction in
response to a given therapy; thereby more effectively treat diseases. For example, clinicians now
commonly test to determine which breast tumors over-express the human epidermal growth
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factor receptor type 2 (HER2), which is associated with a worse prognosis but also predicts a
better response to the medication trastuzumab (Hamburg and Collins 2010). . The development
of tools for high-throughput analysis has increased the determination of biomarkers that can be
used for personalized medicine. Characterization of various biomarkers could aid in the
avoidance of harmful adverse effects and maximize treatment success. Additionally, assessment
of an individual’s susceptibility to certain diseases before they become apparent should also be
possible. The use of biomarker signatures for predicting onset and prognoses of diseases allows
time to set out a plan for prevention, treatment and monitoring that is specific for an individual
patient.

The Links between Stress and the Immune Response
The immune system is a highly regulated system which is divided into innate and
adaptive responses. The nervous system plays a role in the regulation of immunity through
neuroendocrine responses which control inflammation at a systemic level via two axes; the
hypothalamic-pituitary-adrenal axis (HPA axis) and the sympathetic-adrenal medullary (SAM)
axis (Sternberg 2006). The central cells of the immune system (lymphocytes, monocytes, etc.)
display receptors for some neuroendocrine products of the HPA and SAM axes (Padgett and
Glaser 2003). Chronic stress is associated with the activation of the hypothalamic–pituitary–
adrenal (HPA) axis, as well as with the depression of immune function. Acute stress is associated
with activation of the sympatho–adreno–medullary system, which is reflected by salivary aamylase and chromogranin A (Soo-Quee Koh and Choon-Huat Koh 2007).
Psychological stressors increase glucocorticoid levels through increased adrenal activity
which leads to an inhibition of the functions of lymphocytes, macrophages and monocytes.
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Chronic activation of the HPA axis and the SAM axis, results in chronic production of
glucocorticoid hormones and catecholamines (Padgett and Glaser 2003). Glucocorticoid
receptors expressed on a variety of immune cells bind cortisol which indirectly regulates the
activity of immune cells capable of producing cytokines. Adrenergic receptors bind
catecholamines (epinephrine and norepinephrine) and activate the transcription of genes
encoding for a variety of cytokines. The changes in gene expression mediated by glucocorticoid
hormones and catecholamines can lead to immune system dysregulation. The relationship
between stress, the HPA endocrine system and immunity is complex. The multi-directional
relationship between the different systems of the body provide the foundation to my hypothesis
that different forms of stress will affect the nervous, endocrine, and immune systems in unique
ways that are reflected in the unique biomarker signatures associated with each stress.

Biomarker Signatures of Various Stress Forms: Literature Review
An enormous amount of work has been done linking conditions such as post-traumatic
stress disorder (Gill et al. 2009), psychologically stressful situations (Depke et al. 2009) and
various chemical exposures (Pruett et al. 2009) to various immune-altering effects. As high
throughput technology becomes more popular and the technology more accurate, biomarker
signatures of many conditions have been studied as potential diagnostic tools, prognosis
predictors, as well as means to determine the most effective treatment options.

Biomarker Signature of Traumatic Brain Injury
Traumatic brain injury (TBI) is a complex injury with a broad spectrum of symptoms,
disabilities, and causes. Brain damage occurs as a consequence of an external force in the form
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of a direct impact or by acceleration or deceleration alone. The nature of the forces which cause
trauma to the brain determine both the pattern and extent of damage, for example blast waves
from an explosion have been identified as a cause of TBIs with specific characteristics (Maas,
Stocchetti, Bullock 2008)(Maas, Stocchetti, Bullock 2008)(Maas, Stocchetti, Bullock
2008)(Maas, Stocchetti, Bullock 2008)(Maas, Stocchetti and Bullock 728-741)(Maas, Stocchetti,
and Bullock 2008, 728-741)(Maas, Stocchetti, and Bullock 2008, 728-741). In addition to the
damage caused at the time of injury, brain trauma causes secondary injury, a variety of events
that take place in the hours and days following the injury. These events include neurotransmitter
release, free-radical generation, calcium mediated damage, gene activation, mitochondrial
dysfunction, and inflammatory responses (Maas, Stocchetti, Bullock 2008). This secondary
damage creates opportunities for medical intervention and targeted therapies to improve the
outcome for the patient. Currently the common treatment of TBI revolves around standardized
approaches that follow predetermined guidelines for all patients. Knowledge of biomarker
signatures of TBI diagnosis and potential outcome predictors could steer interventions and
targeted therapies in the right direction for TBI victims.
Biomarkers of physical brain injury can classify injury severity level as well as provide a
prediction of the secondary damage which may occur in a specific patient. A number of studies
have shown that the levels of a multitude of brain-specific proteins are altered both in
cerebrospinal fluid (Buttram et al. 2007) and in blood (Berger et al. 2007)(Hergenroeder et al.
2008)(Honda et al. 2010)(Rhind et al. 2010) are altered following a TBI. Using liquid
chromatography-tandem mass spectrometry (LC-MS/MS), 31 proteins whose serum levels were
altered were identified in TBI patients (Hergenroeder et al. 2008). In the three days following a
TBI, serum levels of glial fibrillary acidic protein (GFAP), neuron-specific enolase (NSE) and S-
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100B proteins are increased in patients who had suffered a TBI when compared to the control
group (Honda et al. 2010). Mean serum concentrations of Hsp70 were significantly higher in TBI
patients than in the control group (da Rocha et al. 2005). Many inflammatory and coagulation
proteins may serve as candidate biomarkers of different characteristics of a TBI soon after the
injury takes place.
In the period following the initial injury, biomarker levels may serve as indicators of
injury severity and prospective outcome. At all post-injury time points, higher serum levels of
NSE, S100B, and myelin basic protein (MBP) were associated with worse outcome for children
who had suffered from a TBI (Berger et al. 2007). In addition, serum tau protein levels in TBI
patients at the time of hospital admission correlated with poor outcome (Liliang et al. 2010).
Serum retinol binding protein 4 (RBP4) levels may serve as a predictor of a subsequent increase
in intracranial pressure (Hergenroeder et al. 2008). Increased levels of Hsp70 are also seen in
TBI victims with an increased possibility of death indicating a direct correlation between this
biomarker and severity of the TBI (da Rocha et al. 2005).
TBI provokes marked differences in an abundance of serum protein levels. In many
studies, three biomarkers were individually measured using enzyme-linked immunosorbent
assays. Using sensor-chip technology, multiple biomarkers associated with various time points of
TBI, severity, and likely outcome could be simultaneously assessed. Classification of serum
biomarkers in TBI patients may be useful in the prediction of secondary pathologies as well as in
estimating the effectiveness of various therapeutic agents. Further research on the biosignatures
of traumatic brain injuries of all severity levels could lead to better injury classification and
therefore patient-specific therapies to improve the outcome of TBI patients.
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Biomarker Signatures of Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a condition characterized by persistent synovitis, systemic
inflammation, and the presence of specific autoantibodies (particularly to rheumatoid factor (RF)
and citrullinated peptide(CCP)) which affect many tissues and organs, but mainly attack synovial
joints. Uncontrolled active rheumatoid arthritis causes joint damage, disability, decreased quality
of life.
Characterizing the biomarkers associated with RA onset can be useful in predicting the
disease before symptoms become apparent and selecting the most advantageous treatment.
Studies using enzyme-linked immunosorbent assays have shown that anti-citrullinated peptide
(ACPA), anti- mutated citrullinated vimentin (MCV) and IgM RF can be detected up to 10 years
before RA diagnosis (Turesson et al. 2010).Additional prognostic markers studied include Creactive protein (CRP) or erythrocyte sedimentation rate (ESR), ACPA , and rheumatoid factor
(RF), or matrix metalloproteinase-3 (a proteolytic enzyme which is thought to play a pivotal role
in joint destruction in RA) (Klareskog et al. 2008)(Mamehara et al. 2010). Biomarkers have also
been used to predict the effectiveness of specific treatments on patients with RA. Results suggest
T-lymphocyte expression of CD91 is a biomarker that signifies unresponsiveness to anti-TNF
therapy, a biological disease modifying anti-rheumatic drugs (DMARDs) used to slow down the
progression of joint destruction. Therefore CD91 expression may be used to identify potential
responders and non-responders (Eriksson, Rantapaa-Dahlqvist, Sundqvist 2010). Developing a
method to identify biomarker signatures associated with RA can be useful in preventing the
appearance of disease symptoms and providing effective treatment.
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Biomarker Signatures Associated with Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common form of dementia. The disease is
incurable, degenerative, and terminal. Studies have been done using cerebrospinal fluid to
identify biomarker signatures of the disease. Establishing a profile for the biomarkers of this
disease might serve as signatures for the presence of Alzheimer’s pathology, and aid in the
identification of patients suffering from Alzheimer’s among elderly individuals with late-life
cognitive impairment.
Using the Luminex assay, it was found that the CSF biomarker signature of AD are
defined by Aβ1-42 and t-tau. This signature appears to predict conversion from mild cognitive
impairment to Alzheimer’s (Shaw et al. 2009). Increased levels of tau in CSF are thought to
occur after its release from damaged and dying neurons and tangles, large-scale accumulation of
this least soluble of Aβ peptides into insoluble plaques in the AD brain, lead to decreased CSF
levels of Aβ1-42. The combination of increased CSF concentrations of tau proteins, t-tau and
phosphotau (p-tau), and the decreased concentrations of Aβ1-42 in a patients CSF are considered
to be a pathological biomarker signature that can be used as a diagnostic tool for Alzheimer’s
(Frank et al. 2003).
Among the CSF biomarkers studied, CSF Aβ1-42 concentration appears to be the most
sensitive analyte for the detection of AD, thereby indicating that CSF Aβ1-42 is the most
informative single biomarker (Shaw et al. 2009). The use of the single biomarker Aβ1-42is
inadequate as there is a portion of the healthy population who has higher levels of this indicator.
A panel of biomarkers would be more useful means of diagnosing Alzheimer’s, predicting which
individuals will progress to AD, as well as for monitoring the response of patients to various
therapies in the hopes of developing improved treatment methods.
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Additional Uses of Biomarker Signatures
In addition to the previously mentioned conditions, biomarker signatures are being
characterized for multiple other uses. Biomarker signatures are being studied as a potential
method to predict allograft tolerance for the identification of patients who can lower their
amounts of immunosuppressive therapy, and as predictors of allograft rejection, so that damage
can be prevented (Hernandez-Fuentes and Lechler 2010). Also, microarray analysis showed over
1,500 genes exhibited significantly different expression level in saliva between oral cancer
patients and controls. Seven of these cancer-related mRNA biomarkers exhibited at least a 3.5fold increase in the saliva of oral squamous cell carcinoma (OSCC) patients. Combinations of
salivary RNA biomarkers allowed for distinguishing patients suffering from OSCC from the
control group (Li et al. 2004).

EXPERIMENT BACKGROUND
Post Traumatic Stress Disorder
Biomarker signatures will be sought in human saliva samples taken from patients who
have experienced traumatic situations. This model will allow us to determine unique and
distinctive changes to the biomarker signature in exposed individuals before the onset of post
traumatic stress disorder (PTSD). PTSD is a severe anxiety disorder that can develop after
exposure to any event (physical or psychological) that result in psychological trauma. The
Posttraumatic Stress Diagnostic Scale (PDS) is a questionnaire used to aid in the detection and
diagnosis of PTSD. The PDS yields a total severity score (ranging from 0 to 51) that largely
reflects the incidence of the symptoms of PTSD. Symptoms of PTSD include experiencing
recurrent and intrusive recollections of the stressful event and persistent avoidance of things that
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remind them of the traumatic event. A PDS score provides diagnostic status, a count of the
number of symptoms experienced, a rating of symptom severity, and a rating of the level of
impairment of functioning. A drawback to the PDS is that administration of the questionnaire
takes one to two hours. Symptoms of PTSD can last a long time and can be significant enough to
cause impairment in social, occupational, or other areas of functioning.
Efforts to prevent PTSD have been classified as either primary (intervention prior to the
traumatic event) or secondary (intervention after the trauma) (Fletcher, Creamer, Forbes 2010).
Due to the effect PTSD has on the lives of people who suffer from it as well as the effects PTSD
has on the family of sufferers and on society, prevention and early treatment would be of
extremely advantageous. In addition, the frequency of treatments which are ineffective is far too
great, therefore having an early indicator of PTSD would be of great benefit to individuals
(Fletcher, Creamer, Forbes 2010). PTSD creates an increased risk for illness in an individual as
patients with a history of PTSD have long-lasting immune dysfunction. It has been shown that
the number of lymphocytes, NK cell activity, and total amounts of certain immune related
chemokines were significantly lower in patients with a past history of PTSD (Kawamura
2001).Characterizing biomarker signatures associate with the development of PTSD following a
traumatic event would be greatly useful in determining when treatment would be helpful and in
improving the quality of life for the PTSD patient.

Saliva as a Diagnostic Tool
Saliva samples are easily accessible and have been shown to serve as a useful analyte for
protein markers because saliva composition is influenced by many factors (Esser et al. 2008).
The use of saliva as a medium for biomarker signatures has not been popular in the past due to
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the low concentration of these markers in saliva when compared to serum. This has changed due
to the development of highly sensitive and high-throughput assays such as microarray, mass
spectrometry, reverse transcriptase polymerase chain reaction (RT-PCR), and other technologies
which can be used to measure proteins even at concentrations found in saliva. Many biomarkers
are measurable in saliva, including heavy metals, hormones (e.g. cortisol and
dehydroxyepiandrosterone (DHEA)), toxins and their metabolites, enzymes, immunoglobulins,
other proteins and DNA (Soo-Quee Koh and Choon-Huat Koh 2007).
About 18% of the saliva protein composition is involved in the immune response (Esser
et al. 2008). It has also been found that there is an increase in the secretion of salivary stress
biomarkers (salivary alpha amylase and salivary cortisol) under different stressful conditions
(Wagner et al. 2009). Chronic stress is associated with an increase in salivary cortisol, as well as
with the depression of immune function seen by a decrease in by salivary IgA and lysozyme
levels. Acute stress is associated with activation of the sympatho–adreno–medullary system,
measured by salivary a-amylase and chromogranin A (Soo-Quee Koh and Choon-Huat Koh
2007). These features of human saliva make it a simple an euseful analyte for diagnostic
purposes. Possible limitations to using saliva as a diagnostic biofluids are normal variations
among the population and difficulty storing the sample.

TECHNOLOGIES FOR BIOSIGNATURE ANALYSIS
Surface Plasmon Resonance (SPR) assays represent a novel approach to signature
measurements. A surface plasmon is a traveling, temporary electromagnetic wave caused by
charge-density oscillation at a metal-dielectric interface. Surface plasmon resonance can be
employed to make sensitive measurements of molecular binding interactions. One way in which
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SPR technology is utilized is by protein detecting microarrays. These assays utilize a wide
variety of capture agents (antibodies, fusion proteins, DNA⁄RNA aptamers, synthetic peptides,
carbohydrates, and small molecules) immobilized on a solid surface. (Tomizaki, Usui, Mihara
2010). Each capture agent binds selectively to its target protein in a complex mixture, such as
serum or saliva samples. Captured proteins are subsequently detected and quantified in a highthroughput fashion, with minimal sample consumption.
SPR technology is used in high content assays with improved sensitivity compared to
standard fluorescent microarrays (Unfricht et al. 2005). This high sensitivity assay allows the
measurement of immune system biomarkers that are normally found in very low concentrations
in body-fluid samples that are easily obtained, such as saliva. By measuring 102 – 103 biomarkers
simultaneously, it is possible to reveal patterns of biomarker expression that are indicative of
stressed or diseased states.

Grating-Coupled Surface Plasmon Enhanced Fluorescence (GCSPEF)
The optical phenomenon of surface plasmon resonance can be employed to make
sensitive measurements of molecular binding interactions. For detection of small molecular
weight or low concentration biomarkers, the generated surface plasmon can be used to enhance
fluorophore excitation (Surface plasmon enhanced fluorescence; SPEF) and improve optical
collection efficiency from fluorescently labeled secondary antibodies or biomarkers directly
labeled in a sample. GCSPEF introduces the use of fluorescent tags attached to a captured
analyte (Figure 1). This technology was developed by the Lynes laboratory in collaboration with
the biotechnology company Ciencia Inc. GCSPEF can be used for cell-based assays, protein
assays, and many other functional purposes i.e. to obtain a measurement of cell function by
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means of measuring the soluble proteins secreted from stimulated cells (Jin et al. 2006).
Advantages of GCSPEF over more widely used techniques include its need for small sample size
( 1 ml), microvolumes of detection reagents, and for its ability to measure hundreds of
simultaneous real-time measurements of different analytes.
In GCSPEF the analyte is flowed over a sensor chip which has been prepared with
specific immobilized receptors (which can be antibodies or other proteins). The sensor chips are
covered with a gold surface. During an experiment, the captured analystes are illuminated with
light that couples with the electrons on the grated surface of the gold plated GCSPEF chip to
form a surface Plasmon (Jin et al. 2006). Because plasmons do not propagate far into gold,
hundreds to thousands of interactions can be analyzed on one chip. Sensor chips will be
configured with capture reagents that measure proteins of interest (e.g. cytokines, stress
hormones, antibodies, and other soluble factors). Antibodies or capture ligands are covalently
attached to the gold surface of sensor chips on spots, called Regions of Interest (ROIs) which
allows for specific binding of analytes or cells to occur which changes the refractive index at the
interface.
GCSPEF is able to detect and measure the presence of hundreds of different analytes
simultaneously from a small sample volume. ROIs are spatially organized on a gold-plated
sensor chip so that the specific binding of different analytes in a mixed sample can be measured
simultaneously by passing the sample over the sensor chip and recording changes in the SPR
angle at different ROIs. As an analyte is captured on a ROI, the SPR angle (the angle of minimal
reflection due to maximum coupling) increases. The camera within the GCSRPI machine scans
through a variety of angles to find the SPR angle, which is dependent upon the index of
refraction at the metal interface. The SPR angle can be increased due to interactions between
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analytes and immobilized capture molecules on the chip which that cause an increase in the
index of refraction. The SPR angle can be correlated to the amount of analyte that has bound.
GCSPEF will be specifically useful in my project since hundreds of different regions of the chip
can be independently analyzed simultaneously using sub-milliliter sample volumes (Unfricht et
al. 2005).

Surface Plasmon Enhanced Fluorescence (SPEF)
The Surface Plasmon Enhanced Fluorescence, SPEF, assay allows for increased
sensitivity for detection and quantification of analytes that are too small or too dilute to be
detected by traditional GCSPEF. For detection of small molecular weight or low concentration
biomarkers, the generated surface plasmon can be used to enhance fluorophore excitation to
improve the optical collection efficiency from fluorescently labeled secondary antibodies (Figure
3). Due to the sensitivity of the SPEF assay, it is ideal for highly sensitive fluorescent protein
microarrays. Gold plated chips are used in the SPEF assay because a metal dielectric interface is
needed for SPR. The two platforms (GCSPEF and SPEF) utilize the same chip and the same
machine; therefore independent measurements can be made using both methods from the same
ROIs in sequence during a single experiment.
The SPEF assay can utilize a traditional sandwich immunoassay format (Figure 2) which
enables the large-scale analyses of protein interactions across the entire proteome in a highthroughput fashion with less consumption of the sample. Capture agents are immobilized on a
gold surface and target proteins in the sample are captured. Fluorescently conjugated detection
antibodies are then flowed over the chip which allows for the measurement of captured proteins
in specified ROIs. The SPEF assay is a high content technology, many measurements from the
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same sample can be done simultaneously. The technology is versatile in that many different
types of biomarkers can be measured in conjunction with one another. The high sensitivity of the
system allows for the use of small sample volume, a very useful feature of the technology in
diagnostic sciences since sample sizes are often extremely limited.
In the future, new instruments can be used in order to reduce both cost and size of
instruments so that these technologies can move from the laboratory to the field to be used in
clinical diagnostics. There are also opportunities to improve the sensitivity of the system by
increasing the amounts of immobilized capture molecules, properly orienting the capture
molecule for maximum accessibility of analyte to binding sites, and minimizing non-specific
binding which affects the net sensitivity of the assay. One current approach is the coating of
chips with various surface chemistries that allow for more predictable orientation of binding of
the capture molecule (Jin et al. 2006).

Salivary Biomarkers of Stress Project
Saliva samples were collected from trauma patients at two different time points following
the initial injury. In order to quantify the differential expression profiles of interleukins,
chemokines, TNF and interferon families, and other related stress proteins (e.g. heat shock
proteins, melatonin, and procalcitonin) traditional enzyme-linked immunosorbent assay (ELISA)
as well as surface Plasmon enhanced fluorescence (SPEF) techniques were utilized.

MATERIALS AND METHODS
Saliva samples were collected by our collaborators at UCLA from patients who had been
assaulted (either shot or stabbed. Saliva samples were collected using a “lollipop” style device
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that patients suck on. The device has a filter and the salivary fluid is absorbed through it and
collected. Roche complete protease inhibitor cocktail tablets were used for stable storage of the
samples. Saliva samples were frozen in microcentrifuge tubes. The saliva samples were shipped
frozen to the University of Connecticut. Samples were stored in the -80oC ultrafreeze until ten to
fifteen minutes before they were analyzed.. Samples were allowed to thaw by remaining at room
temperature for around ten minutes.
The enzyme-linked immunosorbent assay (ELISA) can also be used to detect the
presence and concentrations of an antibody or antigen analyte in a sample. An unknown amount
of the analyte is captured by specific antibodies which have been fixed to a well surface.
Secondary antibody linked to an enzyme is then washed over the surface so that it may bind to
antigen captured previously. A substrate is then added which the enzyme can convert to a
detectable, colored signal whose absorbance can be measured by spectrophotometer.

ELISA Protocol for Salivary Biomarkers-Alpha Amylase and Salivary Cortisol
To determine the saliva sample dilution with PBS-T (dissolve 8g of NaCl, 0.2g of KCl,
1.44g of Na2HPO4, 0.24g of KH2PO4, and 2ml of tween-20 in 800 ml of distilled H2O, adjust pH
to 7.2 and adjust volume to 1L with additional distilled H2O) that should be used for SPEF
analysis, enzyme-linked immunosorbent assays were done on various analytes including salivary
alpha-amylase and cortizol. 96-well Immulon 2 HB plates (Dynatech Laboratories, Inc.) were
coated in triplicate with capture antibody (mouse anti amylase at 1 µg/mL from Santa Cruz or
mouse anti cortisol from ABD serotech) with 100ul per well. Plates were incubated overnight at
4oC. Plates were then washed with PBS-T (PBS with 0.2% NaN3 and 0.005% Tween 20, pH 7.2)
using the ELx405 autoplate washer. The wells were then blocked with 2%BSA in PBS-T using
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200µl per well and incubated for 1 hour at 37o C. Plates were washed again before adding
standard human salivary amylase or human salivary cortisol dilutions starting with 1 mg/ml in
PBS-and continuing with an 11-step doubling dilution series (100ul/well). Plates were incubated
for 2 hours at 25oC and then washed again as done previously. The detection antibody cocktail,
(detection anti-amylase, goat polyclonal IgG from Santa Cruz or polyclonal rabbit anti-cortisol
from ABD Serotech) 1 ug/mL in PBS-T, was added (100µL/well) and incubated for 2 hours at
25oC. 100 µL of detection anti-goat IgG-biotin antibody (Rabbit Anti-Goat IgG-Biotin from
Southern Biotech at 0.5 mg/mL) at 1/5000 in PBS-T was added to each well and incubated for 1
hour at 37oC. Plates were washed then Streptavitin-conjugated alkalike phosphate at a dilution of
1/500 (100µL/well) was then added to each well and plates were incubated for 20 minutes at
37OC before a final wash. Wells were then coated with 100 µL substrate buffer (9.7 mL
diethylamine, 0.01 g of MgCl2·6 H20, 0.02 g NaN3 and 90 mL H20, pH 9.8) containing one mg
para-nitrophenylphosphate (PNPP) per mL. A kinetic plate read at 405nm was performed for ten
minutes using a SpectraMax M2 plate reader (Molecular Devices). Nonlinear regression software
(SOFTmax PRO from Molecular Devices) was used to generate a best-fit curve and its equation.

ELISA Protocol for IL-1beta
To determine the saliva sample dilution (with PBS-t) that should be used for SPEF
analysis, enzyme-linked immunosorbent assays was also done on IL-1 beta. 96-well Immulon 2
HB plates (Dynatech Laboratories, Inc.) were coated in triplicate with capture antibody (Mouse
anti-human IL-1β with 2 ug/mL PBS-t from R&D Systems with 100ul per well. Plates were
incubated overnight at 4oC. Plates were then washed with PBS-T (PBS with 0.2% NaN3 and
0.005% Tween 20, pH 7.2) using the ELx405 autoplate washer. The wells were then blocked
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with 2%BSA in PBS-T using 200ul per well and incubated for 1 hour at 37o C. Plates were
washed again before adding standard human salivary IL-1 beta dilutions from 2,000 pg/ml in
PBS-t and unknown dilutions in halves from 1:5 for an 11 step dilution series (100ul/well).
Plates were incubated for 2 hours at 25oC and then washed again as done previously. The
detection antibody cocktail, biotinylated goat anti-human IL-1β-biotin at 400 ng/mL with PBS-T
1 ug/mL was added (100µL/well) and incubated for 2 hours at 25oC. Plates were washed then
Streptavitin-conjugated alkaline phosphate at a dilution of 1/500 (100µL/well) was then added to
each well and plates were incubated for 20 minutes at 37OC before a final wash. Wells were then
coated with 100 µL substrate buffer (9.7 mL diethylamine, 0.01 g of MgCl2·6 H20, 0.02 g NaN3
and 90 mL H20, pH 9.8) containing one mg mg para-nitrophenylphosphate (PNPP) per mL. A
kinetic plate read at 405nm was performed for ten minutes using a SpectraMax M2 plate reader
(Molecular Devices). Nonlinear regression software (SOFTmax PRO from Molecular Devices)
was used to generate a best-fit curve and its equation.

SPR Chip Preparation
SPR sensor chips were washed with 95% ethanol (EtOH) exhaustively for 30 sec. The
chips were then washed exhaustively with ddH2O for 60 sec. Chips were dried under filtered
pressurized air and placed into a plastic chip holder to keep clean until printing. In order to print
capture antibodies onto the gold surface of the chips, a 384 well plate was used, v-bottomed
wells (Table 1) were filled with their respective antibody solutions to spot capture antibody
microarray on the cleaned gold chip. The printing program used for biomarker signature analysis
in all human saliva samples was written using the Spotblot II software. Chips were printed under

Rich, 20

Chana L. Rich

University Scholar Thesis

high humidity using a robotic spotter by Arrayit Microarray Technology. Chips were kept in the
humidity chamber of the robotic spotter for 60 minutes before use.
To analyze sample set two saliva samples, the chemical cross-linker
dithiobis(succinimidyl propionate), DSP, was coated on the gold surface of the chips in order to
improve the method for immobilizing proteins on the chip surface. 4 mg of DSP, dithiobis
(siccinimidyl propionate) from Thermoscientific were dissolved in 1 mL of dimethylsulfoxide
(DMSO) from Fisher Scientific. 300 µL of the solution was spread over the gold surface and
allowed to sit for 30 minutes. The chips were then washed by rinsing them with DMSO followed
by a rinse with ddH2O. Spotting proteins to the activated gold surface was done immediately
following the DSP coating.
SPEF sensor chips with was washed with 95% EtOH exhaustively for 30 seconds then
washed exhaustively with ddH2O for 60 sec. Chips were dried under filtered pressurized air and
placed into a plastic chip holder to keep clean until printing. In order to print capture antibodies
onto the gold surface of the chips, a 384 well plate was used, v-bottom wells were filled with
their respective antibody solutions (Table 1) to spot capture antibody microarray on the cleaned
gold chip. The printing program was made using the Spotblot II software for this experiment to
be used for biomarker signature analysis in all human saliva samples. Chips were printed under
high humidity using a robotic spotter from Arrayit Microarray Technology. Chips were allowed
to stand for 60 min in the humidity chamber of the robotic spotter before proceeding.

Sample Analysis Protocol
Bench top chip fluidic device was washed by circulating PBS-T through the fluidics at
high speed for 5 min. Fluidics were then primed with 2% BSA in PBS. Dry, printed chips were
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inserted into the chip-holding chamber and were blocked using 2% BSA in PBS at 0.5 ml/min
for 30 min. The chips were then washed by running PBS-T at 0.5 ml/min for 5 min. Saliva
samples were thawed immediately before use. Human saliva sample (0.25 ml) was diluted with
PBS-T up to a total volume of 1.5 ml (1:5 dilutions). One ml of sample was drawn into the
fluidics before shunting the end of the waste tube back into the sample holder. The sample was
recirculated at 0.5 ml/min for 60 minutes. The chip was then washed by running PBS-T at 0.5
ml/min for 5 min. 1.5 ml of detection antibody cocktail in PBS-T was recirculated at 0.5 ml/min
for 60 minutes (use Table 2 for antibody information and dilution factors). The chips were then
washed by running PBS-T at 0.5 ml/min for 5 min. Streptavidin-alexa647 cocktail was
recirculated at 0.5 ml/min for 30 min. Chip was washed by running PBS-T at 0.5 ml/min for 10
min. To obtain fluorescent data from the cortisol and amylase secondary detection antibodies, 1.5
ml of anti-goat IgG-alexa647 and anti-rabbit IgG alexa-647 cocktail in PBS-T was recirculated at
0.5 ml / min for 30 min (See Table 3 for reagent dilution factors). Chips were washed by running
PBS-T at 0.5 ml/min for 10 min.
To analyze saliva sample set two, an eight chamber bench top chip fluidic device (a
device with eight separate inflow tubes, chip chambers, and outflow tubes with uniform fluid
movement controlled by a central pump) from Masterplex was primed with 2% BSA in PBS.
Dry, printed chips were inserted into the chip-holding chambers and were blocked using 2%
BSA in PBS at 0.5 ml/min for 30 min. The chips were then washed by running PBS-T at 0.5
ml/min for 5 min across the sensor chip surface. Saliva sample were thawed immediately before
use. 0.25 ml of human saliva sample was diluted with PBS-T to 1.5 ml (1:5 dilution). 1 ml of
diluted sample was drawn into the fluidics before moving the end outflow tube back into the
sample chamber enabling recirculation with the 0.5 ml reserve in the sample tube. The sample
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was recirculated at 0.5 ml/min for 60 minutes. The chip was then washed with PBS-T at 0.5
ml/min for 5 min. 1.5 ml of detection antibody cocktail (Table 2) in PBS-T was recirculated at
0.5 ml/min for 60 minutes (use Table 2 for antibody dilution factors). Chip was washed by
running PBS-T at 0.5 ml/min for 5 min. Streptavidin#alexa647 (from, anti-goat IgG#alexa647
and anti-rabbit IgG alexa#647 (from Invitrogen Molecular Probes) cocktail in PBS-T was
recirculated at 0.5 ml / min for 30 min (Table 3). Chips were washed by running PBS-T at 0.5
ml/min for 10 min. Fluorescent data was read using the SPEF dualmode instrument from
Ciencia.

Data Analysis
Saliva samples were divided into low stress or high stress groups by our collaborators at
UCLA according to their post traumatic stress diagnostic scale (PDS) score (Figure 4). Samples
were collected 2-3 weeks apart and called “visit 1” and “visit 2”. All samples were measured for
the presence of immune/stress associated biomarkers using SPEF microarray. Using both
parametric and non-parametric T-tests, groups were analyzed for differenced between single
biomarkers or for changes in levels of a single biomarker. Parametric tests were useful in
examining the levels of individual biomarkers among groups, while non-parametric tests were
used to compare differences in biomarker levels between groups. Differences in biomarker levels
between groups, and the change in biomarker levels between visits were analyzed for statistically
significant (p≤0.05) differences.
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RESULTS
ELISA Validation of Reagents
Enzyme-linked Immunosorbent Assays (ELISAs) were conducted in order to determine
the saliva sample dilution that should be used for GCSPEF and SPEF assays. A saliva sample
was analyzed in comparison to a standard 11-step dilution series of each biomarker. Alphaamylase was diluted in halves from 1 mg/mL, IL-1 beta from 2000 pg/mL, and salivary cortisol
from 100ng/mL. Control saliva samples and PTSD saliva samples were diluted from a 1:1
dilution to a 1:5 dilution in each experiment. Based on the ELISA results, it was determined that
physiologically relevant measurements of these biomarkers could be made with a saliva sample
dilution of 1:5 in PBS-T.

PTSD Saliva Samples: Sample Set 1
Surface Plasmon enhanced fluorescence (SPEF) was utilized in order to quantify the
differential expression profiles of interleukins, chemokines, TNF and interferon families, and
other related stress proteins (e.g. heat shock proteins, melatonin, and procalcitonin) in saliva
samples obtained from PTSD patients at two different time points. The samples were divided
into four categories, high stress visit 1, high stress visit 2, low stress visit 1, and low stress visit
2. Several patterns are apparent among the biomarkers examined. A complete heat map of all of
sample set 1 can be seen in Figure 6.
Analysis of 39 stress exposed individuals for the presence of 26 immune and/or stress
associated biomarkers revealed one biomarker, MMP-9, that was significantly different between
high and low stress groups (Figure 6). Dividing stress groups samples into 2 visits indicated that
IL-2 levels are significantly higher in the high stress visit 1 group (Figure 7).
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Sample set 1 revealed no significant intergroup variations in the additional biomarkers
examines (as listed in Table 1). Because direct analysis of biomarker levels revealed few
differences between groups, we looked at the changes in the levels of biomarkers that occurred
between visit 1 and visit 2 in each patient. This integrative analysis revealed that levels of Creactive protein (Figure 9) declined more in the low stress group and that levels of cortisol
increased more in the low stress group (Figure 8). Ultimately, our analysis is limited by sample
size and the ability of the PDS to accurately group individuals into high and low stress groups.
However, the observed differences indicate molecular patterns of stress exposure may exist.

PTSD Saliva Samples: Sample Set2
36 saliva samples were analyzed in sample set 2 with the use of DSP surface chemistry
(Figure 10). Dividing stress groups samples into two time points, visits 1 and 2, indicated
significant differences in levels IL-18 binding protein (IL-18 Bpa) among the groups in sample
set 2 (Figure 11). Additionally, we found that levels of IL-8 (Figure 12) and alpha-amylase
(Figure 13) decreased more in the low stress group. Again, our analysis is limited by sample size,
inter-assay variability and the ability of the PDS to accurately group individuals into high and
low stress groups. However, these variations in biomarker level, or changes in biomarker level,
indicate that biomarker signatures of psychological stress exposure may be present.

DISCUSSION
MMPs are a family of enzymes which have the ability to degrade components of the
extracellular matrix. These degrading enzymes are upregulated in inflammatory processes. Our
sample set 1 data revealed levels of salivary MMP-9 that were significantly higher in the low
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stress group when compared to the high stress group . This observation implies that there is an
association between MMP-9 and psychological factors. It was found that there are significant
positive associations between MMP-9 and depression, hostile affect, cynicism, and significant
negative association with a sense of coherence (Garvin et al. 2009). Cancer patients with
elevated symptoms of depression, chronic stress, and low social support also express elevated
MMP-9 levels in tumor associated macrophages as well as in CD68+ cells (Lutgendorf et al.
2008). An explanation for the connection between elevated MMP-9 levels and stress is through
the effects of stress hormones, such as norepinephrine and cortisol. Isolated human macrophages
stimulated with these stress hormones in vitro increased MMP-9 production (Lutgendorf et al.
2008).
Our sample set 1 data also showed higher CRP levels in the high stress when compared to
the low stress group. C-reactive protein (CRP) is a protein found in blood, levels of which rise in
response to inflammation. It has been shown that there is a greater CRP concentration in lower
socioeconomic status (SES) groups defined by occupational status implying an increase in CRP
levels associated with a more stressful lifestyle (Owen et al. 2003). Low SES is associated with
increased risk of coronary heart disease and immune-related disorders which could in part be
reflected by the greater CRP concentration (Owen et al. 2003).
Our sample set 1 data suggests that levels of cortisol increased more in the low stress
group from visit 1 to visit two when compared to the high stress group. Previous research
suggests that a stronger cortisol response at the time of exposure to a traumatic event has a
protective effect against posttraumatic stress disorder symptoms. It was shown that a lower rise
in salivary cortisol levels was associated with an increase in risk of PTSD at both one month and
6 months (Yehuda 2002). However, conflicting data has been found in a separate study. In that
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work, patients who were PTSD positive at 1 month were found to have lower salivary cortisol
levels on the day 2 assessment when compared to those who did not have PTSD (McFarlane et
al. 2010).
In sample set 2, IL-18 binding protein (IL-18 Bpa) was found in increased levels in the
low stress, visit when group when compared to the other three groups. IL-18 binding protein
binds to IL-18 and blocks its biological activity. Therefore, IL-18 is an inhibitor of the Th1
cytotoxic T cell response of the immune system (Novick et al. 1999). Interleukin-18 (IL-18) is a
pro-inflammatory cytokine which plays a role in a variety of conditions and diseases including
infections, autoimmunity, and cancer. IL-18 levels are elevated by activation of the
hypothalamic–pituitary–adrenal (HPA) axis and may be down-regulated by the activation of the
para-sympathetic nervous system (Sugama and Conti 2008). Data obtained in humans or in
animal models demonstrated an association between IL-18 levels and psychiatric disorders
(Sugama and Conti 2008). It has been shown in humans that serum levels of IL-18 were elevated
in depression, panic disorders and other stressful conditions (Kokai et al. 2002). Our data shows
increased levels of an IL-18 inhibitor in the low stress group. Further data analysis and a final
PTSD diagnosis in the patients will be needed to evaluate the linkage between IL-18 binding
proteins and PTSD.
Sample set 2 results indicated that levels of IL-8 and alpha-amylase decreased more in
the low stress group (between visits 1 and 2) when compared to the high stress group. IL-8 is a
chemokine produced by macrophages and other cell types. IL-8 functions as a chemoattractant,
and is also a potent angiogenic factor. It has been shown that serum IL-8 concentration in women
with psychological symptoms was significantly higher than that in women without psychological
symptom indicating a link between IL-8 and psychological stress (Yasui et al. 2007).
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Amylase is a calcium-containing metalloenzyme that hydrolyzes starch in the oral cavity
and is also considered to play an important role in binding to oral bacteria (Nater et al. 2005).
Salivary alpha-amylase levels were found to respond to both physical and psychological stress.
While alpha-amylase levels seem to rise following physical stress, the response to a
psychological stress appears inconsistent (Nater et al. 2005). This inconsistency might be due to
the psychological nature of the stressors employed or due to experimental details, such as
measuring alpha-amylase levels at inappropriate time points. However, other studies have shown
marked increases in salivary alpha-amylase following psychosocial stress, indicating a stressdependent activation of salivary alpha-amylase (Nater et al. 2006).
Our sample set 2 results indicate an increase in salivary alpha amylase 2-3 weeks
following the traumatic event in the high stress group when compared to the low stress group.
The increase in alpha-amylase between visit 1 and visit 2 in the high stress group may be
associated with the greater psychological trauma experienced.

Further Experiments
Further analysis of the data already generated will include combining data from multiple
biomarkers into potential biomarker signatures. Additionally, grouping suites of biomarkers will
be done to assess the presence of immune response types (ex. TH1 vs. TH2 responses, proinflammatory vs. anti-inflammatory responses, etc.). It is possible that an integrative analysis
will reveal patterns or signatures that are characteristic of different types of psychological stress.
Having a molecular mechanism of diagnosing PTSD, quicker diagnosis can be made without
filling out a time-consuming questionnaire (the PDS). A molecular analysis of serum or saliva
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could be used in place of the more traditional psychological screening exams to improve
diagnosis of PTSD and lead to better therapeutic outcomes.
SPEF is a high content assay with improved sensitivity (with detection limits as low as
500 fg/ml) compared to standard fluorescent microarrays. There are other protocol modifications
that could still be examined as ways to further improve the speed and accuracy of the GCSPEF
and SPEF technologies. These modifications include experimentation with different surface
chemistries, different blocking reagents, and altering the antibody and sample concentrations.
Variation between chips, reagents, and assays pose a potential difficulty among inter-assay
comparisons of SPEF experimental results.
Our current research focuses on the measuring salivary biomarkers associated with
psychological stress and trauma. We have already observed significant observable differences
between affected populations and controls for multiple immune biomarkers. By grouping these
differences into patterns we hope it identify signatures of stress associated with disease, trauma,
or toxicant exposure that could be used for clinical diagnosis. Additional statistical analysis
needs to be done to further analyze our data obtained from psychologically stressed patients.
SPEF could be used in the diagnostic world to speed up the diagnosis of many diseases by
looking for many markers of the disease in real time without a requirement for extra labeling
steps, such as fluorescence. SPEF technology may be useful in predicting the development of
post traumatic stress disorder. Utilizing knowledge of biomarker signatures for PTSD, it may be
possible to determine what initially triggered the psychological disorder, making it feasible to
control PTSD before it progresses in severity.
In addition to the previously mentioned purposes, the data collected through our
experiments will provide research supporting the accuracy and wide range of uses for GCSPEF
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and SPEF technologies. Additionally, the saliva experiments further supposed the possibility of
utilizing saliva as a safer, less invasive diagnostic biofluid. To further develop the use of saliva
as a diagnostic biofluid, more research needs to be done to determine the differences in salivary
content throughout the day and night as well as normal differences among the population. The
stability and ideal storage methods of saliva also need to be further examined for ideal accuracy
in the results of studies using saliva as a biofluid.

Future Directions
The use of biomarker signatures to diagnose psychological or chemical stress is a rapidly
expanding field of research. Ultimately, using biomarker signatures, effects of different stresses
may be better predicted and controlled and insight can be provided as to some of the health
consequences which may result. Our experimental protocols and technologies utilized can be
expanded to include a wider variety of stress forms including traumatic brain injury, rheumatoid
arthritis, toxicant exposure, cancer and many other forms of stress. In addition, other biofluids
may be assayed for biomarker signatures (i.e. blood plasma from patients who have been
exposed to various chemical agents). Another application of SPEF technology, in addition to
protein interactions, is cell capture using antibodies to cell-surface protein which provides the
possibility of cell surface biomarker signature studies.
In summary, we have shown that variation in biomarker levels exist among different
stress levels in patients diagnosed with post traumatic stress disorder. These differences in
biomarker levels allow for further statistical analysis top develop patterns of biomarker
signatures of post traumatic stress disorder diagnosis, onset, severity, and the most effective
treatment options. The assays remain to be optimized, and any analysis of the data must take into
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account the differences between protocols utilized, individual experimental assay conditions, and
differences among the samples used. These assays may be used in the future for the study of
additional biological signatures of disease and could provide a novel method of diagnosis.
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FIGURES

Figure 1: GCSPEF Technology Design

Figure 2: Traditional Sandwich Immunoassay Format
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Figure 3: SPEF Technology Design

Figure 4: Biomarker signatures of PTSD Experimental Design
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Figure 5: Results of Sample Set 1 PTSD Saliva Samples; Heatmap

*Experiments completed from 06/08/10-09/10/10
Rich, 34

Chana L. Rich

University Scholar Thesis

Figure 6: Sample Set : 1MMP-9 Data
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Figure 7: Sample Set 1: IL-2 Data
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Figure 8: Sample Set 1: Salivary Cortisol Data
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Figure 9: Sample Set 1: CRP Data
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Figure 10: Results of Sample Set 2 PTSD Saliva Samples; Heatmap

*Experiments completed from 11/17/10-01/10/11
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* Mann-Whitney U test used

Figure 11: Sample Set 2: IL-18 Binding Protein Data
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* Mann-Whitney U test used

Figure 12: Sample Set 2: IL-8 Data
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Figure 13: Sample Set 2: Alpha-amylase Data
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TABLE 1 Microarray Strategy and Design
Analyte
(human)
Dilution buffer
BSA
IL-1 beta

Type

IL-1 ra
IL-2

Anti-inflammatory
Response
Th1 Cytokine

IL-4

Th2 Cytokine

IL-5

Th2 Cytokine

IL-6

Leptin

Inflammatory
cytokine
Inflammatory
cytokine
Anti-inflammatory
cytokine
T cell stimulating
factor
Anti-inflammatory
cytokine
Pro-inflammatory
cytokine
Cell mediated
immunity
cytokine
IL-18 binding
protein
Th2 stimulating
cytokine
Adiposity signal

Interferon-γ

Th1 cytokine

TNF-α

Inflammatory
cytokine
gelatinase

IL-8
IL-10
IL-12
IL-13
IL-17
IL-18

IL-18Bpa
IL-33

MMP-9
C-reactive
protein
Cortisol

Control
control
Inflammatory
Cytokine

Inflammatory
Biomarker
Corticosteroid
hormone

α-amylase

Salivary amylase

MCP-1

Monocyte, Tm
chemokine

Rationale

Detection Strategy

Ab Vendor

Increased in
stress {Miller,
2006 #4}

Goat – poly α-IL-1β-biotin
Str. – Alexa 647

R&D
systems

Goat – poly α-IL-1ra-biotin
Str. – Alexa 647
Goat – poly α-IL-2-biotin
Str. – Alexa 647
Goat – poly α-IL-4-biotin
Str. – Alexa 647
Goat – poly α-IL-5-biotin
Str. – Alexa 647
Goat – poly α-IL-6-biotin
Str. – Alexa 647
Goat – poly α-IL-8-biotin
Str. – Alexa 647
Goat – poly α-IL-10-biotin
Str. – Alexa 647
Goat – poly α-IL-12-biotin
Str. – Alexa 647
Goat – poly α-IL-13-biotin
Str. – Alexa 647
Goat – poly α-IL-17-biotin
Str. – Alexa 647
Rat poly α-IL-18-biotin
Str. – Alexa 647

R&D
systems
R&D
systems
R&D
systems
R&D
systems
R&D
systems
R&D
systems
R&D
systems
R&D
systems
R&D
systems
R&D
systems
MBL

O4

Goat – poly α-IL-18-biotin
Str. – Alexa 647
Goat – poly α-IL-33-biotin
Str. – Alexa 647
Rat – poly α-Leptin-biotin
Str. – Alexa 647
Goat – poly α-IFN-γ-biotin
Str. – Alexa 647
Goat – poly α-TNF-α-biotin
Str. – Alexa 647
Goat – poly α-MMP-9biotin
Str. – Alexa 647
Rat– poly α-CRP-biotin
Str. – Alexa 647
Rabbit – poly α-Cortisol

R&D
systems
R&D
systems
R&D
systems
R&D
systems
R&D
systems
R&D
systems

O15

{Chiappelli, 2006
#5}
{Chiappelli, 2006
#5}

{Chiappelli, 2006
#5}
{Chiappelli, 2006
#5}
{Menon, 2006
#11}

{Wagner,
#8}{Takatsuji,
2008 #10}
increased with
stress
{Wagner, #8}
increased with
stress
{Jiang, 1999 #1},
indirect LPS
response
biomarker in

Plate
position
O1
O2
O3

O5
O6
O7
O8
O9
O10
O11
O12
O13
O14

O16
O17
O18
O19
O20

R&D
systems
AbD
Serotec

O21

Santa
Cruz
Biotechnol
ogy
AbD
Serotec

O23

O22

Dk α -rabbit-Ig – alexa647

Goat – poly α-amylase
Rabbit α-goat IgGalexa647
Goat – poly α-MCP-1biotin
Str. – Alexa 647

O24
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IgA

Secretory Ig

IgG

Human Ig

IgM

Human Ig

IgE

Human Ig

MOPC

Mouse IgG
Negative control
Anti-goat IgGalexa647 positive
control
Anti-rabbit IgGalexa647 positive
control
Streptavidin
alexa647 –
positive control
Protein Block
NSB control
Negative Control

Goat antimouse IgM
Rabbit antimouse CCR3
Biotin-mIgG

BSA
Dilution Buffer

saliva
{Takatsuji, 2008
#10}

M.mono. α-human kappa
light chain- biotin
M.mono α-human lambda
light chain – biotin
Str. – Alexa 647
M.mono. α-human kappa
light chain- biotin
M.mono α-human lambda
light chain – biotin
Str. – Alexa 647
M.mono. α-human kappa
light chain- biotin
M.mono α-human lambda
light chain – biotin
Str. – Alexa 647
M.mono. α-human kappa
light chain- biotin
M.mono α-human lambda
light chain – biotin
Str. – Alexa 647

AbD
Serotec

control

P1

P2

P3

P4

P5

control

Rabbit α-goat Ig –
Alexa647

P6

control

Donkey α-rabbit Ig –
Alexa647

P7

control

Str.-Alexa647

P8

control

P9

control

P10

TABLE 2 Detection Antibody Cocktail: Antibody Dilution Factors
Analyte (human)

Dilution buffer
BSA
IL-1 beta

IL-1 ra

IL-2

IL-4

IL-5

FL
Detection
Strategy
O

2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647

Ab Vendor /
stock ab
concentration

Recommended
working conc. /
dilution range

Working
concentration /
dilution used

Volume of stock
antibody in 1.5
ml PBS-T

R&D systems
50µg /mL

0.1- 0.4 µg /mL

0.25 µg /mL

7.5 µl

R&D systems
50µg /mL

0.1- 0.4 µg /mL

0.25 µg / mL

7.5 µl

R&D systems
50µg /mL

0.1- 0.4 µg /mL

0.25 µg /mL

7.5 µl

R&D systems
50µg /mL

0.1- 0.4 µg /mL

0.25 µg /mL

7.5 µl

R&D systems
250µg /mL

0.5- 2 µg/ mL

1.25 µg/ mL

7.5 µl
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IL-13

IL-17

IL-18

IL-18Bpa

IL-33

Leptin
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TNF-α
MMP-9

C-reactive
protein
Cortisol

α-amylase
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O

2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - rabbit
IgG / antirabbit IgGalexa647
O
2 - goat
IgG / antigoat IgGalexa647
O
2 - biotin* /
avidinalexa647

R&D systems
50µg /mL

0.1- 0.4 µg /mL

0.25 µg /mL

7.5 µl

R&D systems
3.6 µg /mL

20 ng /mL

20 ng /mL

8.3 µl

R&D systems
50µg /mL

0.1- 0.4 µg /mL

0.25 µg /mL

7.5 µl

R&D systems
50µg /mL

0.1- 0.4 µg /mL

0.25 µg /mL

7.5 µl

R&D systems
50µg /mL

0.1- 0.4 µg /mL

0.25 µg /mL

7.5 µl

R&D systems
50µg /mL

0.1- 0.4 µg /mL

0.25 µg /mL

7.5 µl

MBL 1 mg/mL

1:1000 dillution

1:1000
dillution

1.5 µl

R&D systems
36µg /mL

200 ng/ml

200 ng/ml

8.3 µl

R&D systems
50µg /mL

0.1- 0.4 µg /mL

0.25 µg /mL

7.5 µl

R&D systems
250µg /mL

0.5- 2 µg/ mL

1.25 µg/ mL

7.5 µl

R&D systems
9µg / mL

50 ng/ mL

50 ng / mL

8.3 µl

R&D systems
50µg / mL

0.1- 0.4 µg /mL

0.25 µg /mL

7.5 µl

R&D systems
50µg / mL

0.1- 0.4 µg /mL

0.25 µg /mL

7.5 µl

R&D systems
22.5µg / mL

125 ng / mL

125 ng / mL

8.3 µl

AbD Serotec
5mg / mL

?

1:1000

1.5 µl

Santa Cruz
Biotechnology
200 µg / mL

1:30 – 1:3000

1:1000

1.5 µl

AbD Serotec
50 µg/ mL

2- 4µg / mL

0.3 µg / mL

9 µl
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IgA

IgG

IgM

IgE

MOPC
Goat antimouse IgM
Rabbit antimouse CCR3
Biotin-mIgG

University Scholar Thesis
O

2 α-κ + αλ biotin* /
avidinalexa647
O
2 α-κ + αλ biotin* /
avidinalexa647
O
2 α-κ + αλ biotin* /
avidinalexa647
O
2 α-κ + αλ biotin* /
avidinalexa647

AbD Serotec
1mg / mL

1:2000 –
1:4000

1:2000

1 µl

eBioscience
500 µg / ml

1 µg / ml

0.5 µg / ml

1 µl

eBioscience
500 µg / ml

1 µg / ml

0.5 µg / ml

1 µl

eBioscience
500 µg / ml

1 µg / ml

0.5 µg / ml

1 µl

Donkey αgoat Ig –
Alexa647
Donkey αrabbit Ig –
Alexa647
Str.Alexa647

Invitrogen
2mg / ml

1-10 µg / ml

4 µg/ml

1 µl

Invitrogen
2mg / ml

1-10 µg / ml

4 µg/ml

1 µl

Invitrogen
2mg / ml

?

400 ng / ml

2µl stock -> 1 ml
PBS-T, mix, add
150µl to final of
1.5 ml

BSA
Dilution Buffer

Antibodies from R&D Systems
Table 3 Detection Antibody Cocktail: Reagent Dilution Factors
Analyte (human)

Dilution buffer
BSA
IL-1 beta

IL-1 ra

IL-2

IL-4

IL-5

FL Detection
Strategy

O

2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647

Detection reagent
stock
concentration

Detection reagent
working
concentration

Volume of stock det.
reagent in 1.5 ml
PBS-T

Streptavidinalexafluor 647
2mg /ml
Streptavidinalexafluor 647
2mg /ml
Streptavidinalexafluor 647
2mg /ml
Streptavidinalexafluor 647
2mg /ml
Streptavidinalexafluor 647
2mg /ml

200 ng / ml

1 µl of stock in 1 ml
of PBS, mix, add
150 µl
1 µl of stock in 1 ml
of PBS, mix, add
150 µl
1 µl of stock in 1 ml
of PBS, mix, add
150 µl
1 µl of stock in 1 ml
of PBS, mix, add
150 µl
1 µl of stock in 1 ml
of PBS, mix, add
150 µl

200 ng / ml

200 ng / ml

200 ng / ml

200 ng / ml
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IL-6

IL-8

IL-10

IL-12

IL-13

IL-17

IL-18

IL-18Bpa

IL-33

Leptin

Interferon-γ

TNF-α
MMP-9

IgA

C-reactive protein

Cortisol

α-amylase

University Scholar Thesis
O

2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - biotin* /
avidinalexa647
O
2 - rabbit IgG
/ anti-rabbit
IgG-alexa647
O

2 - goat IgG /
anti-goat IgGalexa647

Streptavidinalexafluor 647
2mg /ml
Streptavidinalexafluor 647
2mg /ml
Streptavidinalexafluor 647
2mg /ml
Streptavidinalexafluor 647
2mg /ml
Streptavidinalexafluor 647
2mg /ml
Streptavidinalexafluor 647
2mg /ml
Streptavidinalexafluor 647
2mg /ml
Streptavidinalexafluor 647
2mg /ml
Streptavidinalexafluor 647
2mg /ml
Streptavidinalexafluor 647
2mg /ml
Streptavidinalexafluor 647
2mg /ml
Streptavidinalexafluor 647
2mg /ml
Streptavidinalexafluor 647
2mg /ml
Streptavidinalexafluor 647
2mg /ml
Streptavidinalexafluor 647
2mg /ml
Donkey antirabbit IgG (H+L)
alexa647 2mg/ml

200 ng / ml

5 ug / ml

1 µl of stock in 1 ml
of PBS, mix, add
150 µl
1 µl of stock in 1 ml
of PBS, mix, add
150 µl
1 µl of stock in 1 ml
of PBS, mix, add
150 µl
1 µl of stock in 1 ml
of PBS, mix, add
150 µl
1 µl of stock in 1 ml
of PBS, mix, add
150 µl
1 µl of stock in 1 ml
of PBS, mix, add
150 µl
1 µl of stock in 1 ml
of PBS, mix, add
150 µl
1 µl of stock in 1 ml
of PBS, mix, add
150 µl
1 µl of stock in 1 ml
of PBS, mix, add
150 µl
1 µl of stock in 1 ml
of PBS, mix, add
150 µl
1 µl of stock in 1 ml
of PBS, mix, add
150 µl
1 µl of stock in 1 ml
of PBS, mix, add
150 µl
1 µl of stock in 1 ml
of PBS, mix, add
150 µl
1 µl of stock in 1 ml
of PBS, mix, add
150 µl
1 µl of stock in 1 ml
of PBS, mix, add
150 µl
3.7 µl

Rabbit anti-goat
IgG (H+L)
alexa647 2mg/ml

5 ug / ml

3.7 µl

200 ng / ml

200 ng / ml

200 ng / ml

200 ng / ml

200 ng / ml

200 ng / ml

200 ng / ml

200 ng / ml

200 ng / ml

200 ng / ml

200 ng / ml

200 ng / ml

200 ng / ml

200 ng / ml
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MCP-1

E. coli

Listeria
monocytogenes
Metallothionein
RF (IgM anti- h IgG)

University Scholar Thesis
O

2 - biotin* /
avidinalexa647
O
2 - biotin /
avidinalexa647
O
2 - biotin /
avidinalexa647
O

Anti-h IgM 2 biotin / avidinalexa647

Streptavidinalexafluor 647
2mg /ml
Streptavidinalexafluor 647
2mg /ml
Streptavidinalexafluor 647
2mg /ml

200 ng / ml

Streptavidinalexafluor 647
2mg /ml

200 ng / ml

200 ng / ml

200 ng / ml

1 µl of stock in 1 ml
of PBS, mix, add
150 µl
1 µl of stock in 1 ml
of PBS, mix, add
150 µl
1 µl of stock in 1 ml
of PBS, mix, add
150 µl
1 µl of stock in 1 ml
of PBS, mix, add
150 µl

MOPC
Goat anti-mouse
IgM
Rabbit anti-mouse
CCR3
Biotin-mIgG
BSA
Dilution Buffer

Rich, 48

Chana L. Rich

University Scholar Thesis

REFERANCES
Berger RP, Beers SR, Richichi R, Wiesman D, Adelson PD. 2007. Serum biomarker
concentrations and outcome after pediatric traumatic brain injury. J Neurotrauma
24(12):1793-801.
Biomarkers Definitions Working Group. 2001. Biomarkers and surrogate endpoints: Preferred
definitions and conceptual framework. Clin Pharmacol Ther 69(3):89-95.
Buttram SD, Wisniewski SR, Jackson EK, Adelson PD, Feldman K, Bayir H, Berger RP, Clark
RS, Kochanek PM. 2007. Multiplex assessment of cytokine and chemokine levels in
cerebrospinal fluid following severe pediatric traumatic brain injury: Effects of
moderate hypothermia. J Neurotrauma 24(11):1707-17.
da Rocha AB, Zanoni C, de Freitas GR, Andre C, Himelfarb S, Schneider RF, Grivicich I,
Borges L, Schwartsmann G, Kaufmann M, et al. 2005. Serum Hsp70 as an early
predictor of fatal outcome after severe traumatic brain injury in males. J Neurotrauma
22(9):966-77.
Depke M, Steil L, Domanska G, Volker U, Schutt C, Kiank C. 2009. Altered hepatic mRNA
expression of immune response and apoptosis-associated genes after acute and chronic
psychological stress in mice. Mol Immunol 46(15):3018-28.
Eriksson C, Rantapaa-Dahlqvist S, Sundqvist KG. 2010. T-cell expression of CD91 - a marker of
unresponsiveness to anti-TNF therapy in rheumatoid arthritis. APMIS 118(11):837-45.
Esser D, Alvarez-Llamas G, de Vries MP, Weening D, Vonk RJ, Roelofsen H. 2008. Sample
stability and protein composition of saliva: Implications for its use as a diagnostic fluid.
Biomark Insights 3:25-7.
Fletcher S, Creamer M, Forbes D. 2010. Preventing post traumatic stress disorder: Are drugs the
answer? Aust N Z J Psychiatry 44(12):1064-71.
Frank RA, Galasko D, Hampel H, Hardy J, de Leon MJ, Mehta PD, Rogers J, Siemers E,
Trojanowski JQ, National Institute on Aging Biological Markers Working Group. 2003.
Biological markers for therapeutic trials in alzheimer's disease. proceedings of the
biological markers working group; NIA initiative on neuroimaging in alzheimer's
disease. Neurobiol Aging 24(4):521-36.
Garvin P, Nilsson L, Carstensen J, Jonasson L, Kristenson M. 2009. Plasma levels of matrix
metalloproteinase-9 are independently associated with psychosocial factors in a middleaged normal population. Psychosom Med 71(3):292-300.

Rich, 49

Chana L. Rich

University Scholar Thesis

Gill JM, Saligan L, Woods S, Page G. 2009. PTSD is associated with an excess of inflammatory
immune activities. Perspect Psychiatr Care 45(4):262-77.
Hamburg MA and Collins FS. 2010. The path to personalized medicine. N Engl J Med
363(4):301-4.
Hergenroeder G, Redell JB, Moore AN, Dubinsky WP, Funk RT, Crommett J, Clifton GL,
Levine R, Valadka A, Dash PK. 2008. Identification of serum biomarkers in braininjured adults: Potential for predicting elevated intracranial pressure. J Neurotrauma
25(2):79-93.
Hernandez-Fuentes MP and Lechler RI. 2010. A 'biomarker signature' for tolerance in
transplantation. Nat Rev Nephrol 6(10):606-13.
Honda M, Tsuruta R, Kaneko T, Kasaoka S, Yagi T, Todani M, Fujita M, Izumi T, Maekawa T.
2010. Serum glial fibrillary acidic protein is a highly specific biomarker for traumatic
brain injury in humans compared with S-100B and neuron-specific enolase. J Trauma .
Jin GB, Unfricht DW, Fernandez SM, Lynes MA. 2006. Cytometry on a chip: Cellular
phenotypic and functional analysis using grating-coupled surface plasmon resonance.
Biosens Bioelectron 22(2):200-6.
Kawamura N, Kim Y, Asukai N. 2001. Suppression of cellular immunity in men with a past
history of posttraumatic stress disorder. Am J Psychiatry 158(3):484-6.
Klareskog L, Ronnelid J, Lundberg K, Padyukov L, Alfredsson L. 2008. Immunity to
citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol 26:651-75.
Kokai M, Kashiwamura S, Okamura H, Ohara K, Morita Y. 2002. Plasma interleukin-18 levels
in patients with psychiatric disorders. J Immunother 25 Suppl 1:S68-71.
Li Y, St John MA, Zhou X, Kim Y, Sinha U, Jordan RC, Eisele D, Abemayor E, Elashoff D,
Park NH, et al. 2004. Salivary transcriptome diagnostics for oral cancer detection. Clin
Cancer Res 10(24):8442-50.
Liliang PC, Liang CL, Weng HC, Lu K, Wang KW, Chen HJ, Chuang JH. 2010. Tau proteins in
serum predict outcome after severe traumatic brain injury. J Surg Res 160(2):302-7.
Lutgendorf SK, Lamkin DM, Jennings NB, Arevalo JM, Penedo F, DeGeest K, Langley RR,
Lucci JA,3rd, Cole SW, Lubaroff DM, et al. 2008. Biobehavioral influences on matrix
metalloproteinase expression in ovarian carcinoma. Clin Cancer Res 14(21):6839-46.
Maas AI, Stocchetti N, Bullock R. 2008. Moderate and severe traumatic brain injury in adults.
Lancet Neurol 7(8):728-41.

Rich, 50

Chana L. Rich

University Scholar Thesis

Mamehara A, Sugimoto T, Sugiyama D, Morinobu S, Tsuji G, Kawano S, Morinobu A,
Kumagai S. 2010. Serum matrix metalloproteinase-3 as predictor of joint destruction in
rheumatoid arthritis, treated with non-biological disease modifying anti-rheumatic
drugs. Kobe J Med Sci 56(3):E98-E107.
McFarlane AC, Barton CA, Yehuda R, Wittert G. 2010. Cortisol response to acute trauma and
risk of posttraumatic stress disorder. Psychoneuroendocrinology .
Nater UM, La Marca R, Florin L, Moses A, Langhans W, Koller MM, Ehlert U. 2006. Stressinduced changes in human salivary alpha-amylase activity -- associations with
adrenergic activity. Psychoneuroendocrinology 31(1):49-58.
Nater UM, Rohleder N, Gaab J, Berger S, Jud A, Kirschbaum C, Ehlert U. 2005. Human salivary
alpha-amylase reactivity in a psychosocial stress paradigm. Int J Psychophysiol
55(3):333-42.
Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M. 1999. Interleukin18 binding protein: A novel modulator of the Th1 cytokine response. Immunity
10(1):127-36.
Owen N, Poulton T, Hay FC, Mohamed-Ali V, Steptoe A. 2003. Socioeconomic status, Creactive protein, immune factors, and responses to acute mental stress. Brain Behav
Immun 17(4):286-95.
Padgett DA and Glaser R. 2003. How stress influences the immune response. Trends Immunol
24(8):444-8.
Pruett SB, Fan R, Zheng Q, Schwab C. 2009. Patterns of immunotoxicity associated with chronic
as compared with acute exposure to chemical or physical stressors and their relevance
with regard to the role of stress and with regard to immunotoxicity testing. Toxicol Sci
109(2):265-75.
Rhind SG, Crnko NT, Baker AJ, Morrison LJ, Shek PN, Scarpelini S, Rizoli SB. 2010.
Prehospital resuscitation with hypertonic saline-dextran modulates inflammatory,
coagulation and endothelial activation marker profiles in severe traumatic brain injured
patients. J Neuroinflammation 7:5.
Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K,
Soares H, Simon A, Lewczuk P, et al. 2009. Cerebrospinal fluid biomarker signature in
alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65(4):403-13.
Soo-Quee Koh D and Choon-Huat Koh G. 2007. The use of salivary biomarkers in occupational
and environmental medicine. Occup Environ Med 64(3):202-10.
Sternberg EM. 2006. Neural regulation of innate immunity: A coordinated nonspecific host
response to pathogens. Nat Rev Immunol 6(4):318-28.
Rich, 51

Chana L. Rich

University Scholar Thesis

Sugama S and Conti B. 2008. Interleukin-18 and stress. Brain Res Rev 58(1):85-95.
Tomizaki KY, Usui K, Mihara H. 2010. Protein-protein interactions and selection: Array-based
techniques for screening disease-associated biomarkers in predictive/early diagnosis.
FEBS J 277(9):1996-2005.
Trusheim MR, Berndt ER, Douglas FL. 2007. Stratified medicine: Strategic and economic
implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov
6(4):287-93.
Turesson C, Bergstrom U, Jacobsson LT, Truedsson L, Berglund G, Saxne T. 2010. Increased
cartilage turnover and circulating autoantibodies in different subsets before the clinical
onset of rheumatoid arthritis. Ann Rheum Dis .
Unfricht DW, Colpitts SL, Fernandez SM, Lynes MA. 2005. Grating-coupled surface plasmon
resonance: A cell and protein microarray platform. Proteomics 5(17):4432-42.
Wagner J, Cik M, Marth E, Santner BI, Gallasch E, Lackner A, Raggam RB. 2009. Feasibility of
testing three salivary stress biomarkers in relation to naturalistic traffic noise exposure.
Int J Hyg Environ Health .
Yasui T, Maegawa M, Tomita J, Miyatani Y, Yamada M, Uemura H, Ueno S, Numata S,
Ohmori T, Tsuchiya N, et al. 2007. Association of serum cytokine concentrations with
psychological symptoms in midlife women. J Reprod Immunol 75(1):56-62.
Yehuda R. 2002. Post-traumatic stress disorder. N Engl J Med 346(2):108-14.

Rich, 52

